Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves 3 Drugs for the Switch From Prescription to Over the Counter

By Brian Orelli, PhD – Updated Feb 28, 2020 at 4:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.

The Food and Drug Administration approved three drugs on Friday to switch from prescription status to being available over the counter: GlaxoSmithKline's (GSK -2.17%) Voltaren Arthritis Pain and two related allergy drugs from Alcon (ALC -2.85%)

The switch, which is typically initiated by the manufacturer, will likely come with a lower cost for the medications, but the companies hope to make up for it with higher volume since patients can walk into a pharmacy and get the medications off the shelf without seeing a doctor. Over the years, many pain, allergy, and heartburn drugs have made the switch after the FDA became more comfortable with their safety.

Pharmacy shelves

Image source: Getty Images.

GlaxoSmithKline's Voltaren Arthritis Pain was originally approved as a prescription drug in 2007 to relieve pain for patients with osteoarthritis. The drug is a nonsteroidal anti-inflammatory drug (NSAID) in the same class as ibuprofen, although it's a topical formulation applied to achy joints. The drug will remain approved for osteoarthritis but not for strains, sprains, and bruises that other NSAIDs are used to treat.

Alcon persuaded the FDA to switch two eye-drop medications that treat itching and red eyes due to allergies. Patanol, which was originally approved in 1996, will now be called Pataday Twice Daily Relief, while Pataday, which was approved in 2004, will now be called Pataday Once Daily Relief. The drugs have the same active ingredient, the antihistamine olopatadine, but the once-a-day formation is a higher strength than the twice-daily formulation.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
$29.36 (-2.17%) $0.65
Alcon, Inc. Stock Quote
Alcon, Inc.
$60.02 (-2.85%) $-1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.